Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
Frontiers in Medicine, doi:10.3389/fmed.2021.704666
Importance/Background: The coronavirus disease (COVID-19) pandemic is a critical public health issue. Evidence has shown that metformin favorably influences COVID-19 outcomes. This study aimed to assess the benefits and risks of metformin in COVID-19 patients.
Methods: We searched the PubMed, Embase, Cochrane Library, and Chinese Biomedical Literature Database from inception to February 18, 2021. Observational studies assessing the association between metformin use and the outcomes of COVID-19 patients were included. The primary outcome was mortality, and the secondary outcomes included intubation, deterioration, and hospitalization. Random-effects weighted models were used to pool the specific effect sizes. Subgroup analyses were conducted by stratifying the meta-analysis by region, diabetic status, the adoption of multivariate model, age, risk of bias, and timing for adding metformin.
Results: We identified 28 studies with 2,910,462 participants. Meta-analysis of 19 studies showed that metformin is associated with 34% lower COVID-19 mortality [odds ratio (OR), 0.66; 95% confidence interval (CI), 0.56-0.78; I 2 = 67.9%] and 27% lower hospitalization rate (pooled OR, 0.73; 95% CI, 0.53-1.00; I 2 = 16.8%). However, we did not identify any subgroup effects. The meta-analysis did not identify statistically significant association between metformin and intubation and deterioration of COVID-19 (OR, 0.94; 95% CI, 0.77-1.16; I 2 = 0.0% for intubation and OR, 2.04; 95% CI, 0.65-6.34; I 2 = 79.4% for deterioration of COVID-19), respectively.
Conclusions: Metformin use among COVID-19 patients was associated with a reduced risk of mortality and hospitalization. Our findings suggest a relative benefit for metformin use in nursing home and hospitalized COVID-19 patients. However, randomized controlled trials are warranted to confirm the association between metformin use and COVID-19 outcomes.
AUTHOR CONTRIBUTIONS YL, ZZ, and SL: conception or design. YL, XY, PY, and TS: acquisition, analysis, or interpretation. YL, XY, PY, TS, ZZ, and SL: drafting the work or revision and final approval of the manuscript. All authors contributed to the article and approved the submitted version.
SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2021.704666/full#supplementary-material
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Bonnet, Scheen, Understanding, and overcoming metformin gastrointestinal intolerance, Diabetes Obes Metab,
doi:10.1111/dom.12854Bramante, Buse, Tamaritz, Palacio, Cohen et al., Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity, J Med Virol,
doi:10.1002/jmv.26873Bramante, Ingraham, Murray, Marmor, Hovertsen et al., Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Healthy Longev,
doi:10.1016/S2666-7568(20)30033-7Bramante, Ingraham, Murray, Marmor, Hovertsen et al., Observational study of metformin and risk of mortality in patients hospitalized with COVID-19,
doi:10.1101/2020.06.19.20135095Bramante, Tignanelli, Dutta, Jones, Tamariz et al., Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for COVID-19,
doi:10.1101/2020.09.01.20185850Buse, Wexler, Tsapas, Rossing, Mingrone et al., update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD), Diabetes Care,
doi:10.2337/dci19-0066Cancer, Fitzmaurice, Abate, Abbasi, Abbastabar et al., Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disabilityadjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study, JAMA Oncol,
doi:10.1001/jamaoncol.2019.2996Cariou, Hadjadj, Wargny, Pichelin, Al-Salameh et al., Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia,
doi:10.1007/s00125-020-05180-xCheng, Liu, Zhang, Lei, Qin et al., Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes, Cell Metab,
doi:10.1016/j.cmet.2020.08.013Choi, Ahn, Ryu, Kim, Jang et al., Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea, J Clin Med,
doi:10.3390/jcm9061959Clark, Jit, Warren-Gash, Guthrie, Wang et al., Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study, Lancet Global Health,
doi:10.1016/S2214-109X(20)30264-3Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, Front Endocrinol,
doi:10.3389/fendo.2020.600439Do, Kim, Park, Cho, Kang, Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?, Diabetes Metab,
doi:10.1016/j.diabet.2020.10.006Gao, Liu, Zhong, Liu, Zhou et al., Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report, Clin Transl Sci,
doi:10.1111/cts.12897Garber, Handelsman, Grunberger, Einhorn, Abrahamson et al., Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive ttype 2 diabetes management algorithm -2020 executive summary, Endocr Pract,
doi:10.4158/cs-2019-0472Griffin, Leaver, Irving, Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes, Diabetologia,
doi:10.1007/s00125-017-4337-9Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med,
doi:10.1056/NEJMoa2002032Hayek, Robert, Matar, Algarni, Alkubedan et al., Risk factors for hospital admission among COVID-19 patients with diabetes a study from Saudi Arabia, Saudi Med J,
doi:10.15537/smj.2020.10.25419Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Huang, Lim, Pranata, Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.04.018Izzi-Engbeaya, Distaso, Amin, Yang, Idowu et al., Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals, BMJ Open Diabetes Res Care,
doi:10.1136/bmjdrc-2020-001858Jiang, Chen, Yin, Liu, Yang et al., Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2020.108619Khunti, Knighton, Zaccardi, Bakhai, Barron et al., Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(21)00050-4Kichloo, Albosta, Dettloff, Wani, El-Amir et al., Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA, Fam Med Community Health,
doi:10.1136/fmch-2020-000530Kim, Jeon, Moon, Cho, Han et al., The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in daegu, South Korea, Diabetes Metab J,
doi:10.4093/dmj.2020.0146Kow, Hasan, Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis, J Med Virol,
doi:10.1002/jmv.26498Lalau, Al-Salameh, Hadjadj, Goronflot, Wiernsperger et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19, Diabetes Metab,
doi:10.1016/j.diabet.2020.101216Lalau, Kajbaf, Protti, Christensen, Broe, Metforminassociated lactic acidosis (MALA): moving towards a new paradigm, Diabetes Obes Metab,
doi:10.1111/dom.12974Lally, Tsoukas, Halladay, Neill, Gravenstein et al., Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2, J Am Med Dir Assoc,
doi:10.1016/j.jamda.2020.10.031Li, Nemeth, Donnelly, Hapca, Zhou et al., Visit-to-visit HbA1c variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes, Diabetes Care,
doi:10.2337/dc19-0823Li, Wei, Li, Mccowen, Xiong et al., Metformin use in diabetes prior to hospitalization: effects on mortality in COVID-19, Endocr Pract,
doi:10.4158/EP-2020-0466Li, Zong, Sun, Li, New evidence-based clinical practice guideline timely supports hospital infection control of coronavirus disease 2019, Precis Clin Med,
doi:10.1093/pcmedi/pbaa008Liu, Bai, Han, Jiang, Qiu et al., The association of diabetes and the prognosis of COVID-19 patients: a retrospective study, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2020.108386Lukito, Pranata, Henrina, Lim, Lawrensia et al., The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.11.006Luo, Qiu, Liu, Liu, Zheng et al., Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0375Matsiukevich, Piraino, Lahni, Hake, Wolfe et al., Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock, Biochim Biophys Acta Mol Basis Dis,
doi:10.1016/j.bbadis.2017.05.027Mirsoleymani, Nekooghadam, Marzaleh, Peyravi, Soltani et al., Assessment of risk factors for severe coronavirus disease 2019 among Iranian patients, Iran Red Crescent Med J,
doi:10.32592/ircmj.2020.22.9.72Moher, Liberati, Tetzlaff, Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med,
doi:10.1371/journal.pmed.1000097Nafakhi, Alareedh, Al-Buthabhak, Shaghee, Nafakhi et al., Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.12.014Orioli, Servais, Belkhir, Laterre, Thissen et al., Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: a retrospective study from an academic center in Belgium, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.12.020Palmer, Tendal, Mustafa, Vandvik, Li et al., Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ,
doi:10.1136/bmj.m4573Park, Lee, Park, Park, Cheon et al., Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients, World J Gastroenterol,
doi:10.3748/wjg.v23.i28.5196Perez-Belmonte, Torres-Pena, Lopez-Carmona, Ayala-Gutierrez, Fuentes-Jimenez et al., Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study, BMC Med,
doi:10.1186/s12916-020-01832-2Petrie, Rossing, Campbell, Metformin, and cardiorenal outcomes in diabetes: a reappraisal, Diabetes Obes Metab,
doi:10.1111/dom.13984Simonnet, Chetboun, Poissy, Raverdy, Noulette et al., High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity,
doi:10.1002/oby.22831Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol,
doi:10.1007/s10654-010-9491-zTan, Wang, Liu, Shi, Zhou et al., Long-acting metformin vs. Metformin immediate release in patients with type 2 diabetes: a systematic review, Front Pharmacol,
doi:10.3389/fphar.2021.669814Vj, Illescas-Montes, Puerta-Puerta, Ruiz, Melguizo-Rodríguez, SARS-CoV-2 infection: the role of cytokines in COVID-19 disease, Cytokine Growth Factor Rev,
doi:10.1016/j.cytogfr.2020.06.001Wang, Cooper, Gokhale, Acosta-Mena, Dhalla et al., Association of metformin with susceptibility to COVID-19 in people with type 2 diabetes, J Clin Endocrinol Metab,
doi:10.1210/clinem/dgab067Wang, Gao, Zhang, Huang, Zhang et al., Prevalence ethnic pattern of diabetes prediabetes in China in 2013, JAMA,
doi:10.1001/jama.2017.7596Wang, Van Oekelen, Mouhieddine, Valle, Richter et al., A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward, J Hematol Oncol,
doi:10.1186/s13045-020-00934-xYang, Tao, Peng, Zhao, Li et al., High-sensitivity C-reactive protein and risk of type 2 diabetes: a nationwide cohort study and updated meta-analysis, Diabetes Metab Res Rev,
doi:10.1002/dmrr.3446Yitao, Mu, Ling, Shiyao, Jiaojie et al., Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study, Curr Med Res Opin,
doi:10.1080/03007995.2021.1876005Zhang, Dong, Martin, He, Gongol et al., AMPactivated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension, Am J Respir Crit Care Med,
doi:10.1164/rccm.201712-2570OCZhang, Li, Li, Li, Ren et al., Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials, Nutrients,
doi:10.3390/nu8120798Zhang, Wang, Zhu, Mao, Bai et al., Risk factors for poor outcomes of diabetes patients with COVID-19: a single-center, retrospective study in early outbreak in China, Front Endocrinol,
doi:10.3389/fendo.2020.571037Zhou, Zhang, Zhang, Zhou, Li et al., Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital, Chin Med J,
doi:10.1097/CM9.0000000000001407Zhu, Zhong, Li, Li, Pang, Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis, Fam Med Community Health,
doi:10.1136/fmch-2020-000406
